• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Humira Rivals Expected to Hit Market This Month

Article

Prices not likely to change upon release.

Hands of a person in red. Image Credit: Adobe Stock Images/ZayNyi

Image Credit: Adobe Stock Images/ZayNyi

In a move to compete with AbbVie’s rheumatoid arthritis drug Humira, drugmakers Boehringer Ingelheim, Sandoz, and Organon are expected to launch copycat versions of the drug this month. Despite price decreases that usually come with generic versions of a previously patented medication, manufacturers are expected to keep prices high in an effort to compete for leverage with pharmacy benefit managers (PBMs), which negotiate insurance coverage on behalf of their customers.

"I don’t foresee anyone changing their pricing policy," said Robert Popovian, chief science policy officer, Global Healthy Living Foundation. He also stated that PBMs might face political pressure to cover Coherus' significantly discounted copy.

Reference: Analysis: New Humira rivals likely to hit US market with small discounts in July. Reuters. June 30, 2023. Accessed June 6, 2023. https://www.reuters.com/business/healthcare-pharmaceuticals/new-humira-rivals-likely-hit-us-market-with-small-discounts-july-2023-06-30/

Related Videos